1. Home
  2. TGTX

as 09-12-2025 11:35am EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Founded: 1993 Country:
United States
United States
Employees: N/A City: NEW YORK
Market Cap: 4.2B IPO Year: 1995
Target Price: $42.50 AVG Volume (30 days): 2.0M
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: 0.36 EPS Growth: -43.55
52 Week Low/High: $21.16 - $46.48 Next Earning Date: 11-03-2025
Revenue: $454,069,000 Revenue Growth: 30.96%
Revenue Growth (this year): 82.58% Revenue Growth (next year): 44.99%

TGTX Daily Stock ML Predictions

Share on Social Networks: